Diferencia entre revisiones de «Foscarnet»
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Línea 6: | Línea 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*CMV retinitis: 90 mg/kg IV q12h '''OR''' 60 mg/kg IV q8h for 2-3 weeks, then maintenance 90-120 mg/kg IV daily | |||
*HSV resistant to acyclovir, immunocompromised: 40 mg/kg IV 2-3 times daily | |||
*VZV resistant to acyclovir, HIV+: 90 mg/kg IV q12h | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Foscarnet]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Foscarnet]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Foscarnet]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Foscarnet]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
Revisión actual - 02:38 20 mar 2026
Administration
- Type: Antiviral
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names: Foscavir
Adult Dosing
- CMV retinitis: 90 mg/kg IV q12h OR 60 mg/kg IV q8h for 2-3 weeks, then maintenance 90-120 mg/kg IV daily
- HSV resistant to acyclovir, immunocompromised: 40 mg/kg IV 2-3 times daily
- VZV resistant to acyclovir, HIV+: 90 mg/kg IV q12h
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| CMV colitis | 90mg/kg IV q12hrs x 21 days | Until symptom resolution |
| CMV neurologic disease | 90mg/kg IV q12hrs x 21 days then 90-120mg/kg IV q24hrs | Combined with Ganciclovir |
| Encephalitis | 90mg/kg IV every 12 hrs | CMV |
Pediatric Dosing
Indications by Disease
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: Complicated dose adjustment required!
- Hepatic dosing: No adjustement
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hyperphosphatemia, hypophosphatemia, hypocalcemia, hypokalemia, hypomagnesemia
- Pancreatitis
- Pancytopenia
- Renal failure, renal impairment
- Seizure
Common
- Nausea, vomiting, diarrhea
- Anemia, granulocytopenic disorder
- Headache
- Fever
Pharmacology
- Half-life: 3.3-4h
- Metabolism:
- Excretion: Renal
Mechanism of Action
- inhibits pyrophosphate binding on viral DNA polymerases